Inhalational vaccination against pulmonary pathogens . . .
hopefully this will be part of the planned future for INSM and the liposome. The data which indicates that the fixed macrophages in the conducting airways and alveoli are the presenting cells of foreign materials to the T lymphocytes in the lung (antibody secreting cells) clearly indicates that any antigen put inside the liposome will present to the immune system of the lungs. That could be SARs, influenza, or any purified/recombinant antigen that produces neutralizing antibodies. It is probably a one, two or three administration use at two week intervals, but it is a substantial breakthrough indication. And millions of people would be treated in a short time frame. The H1N1 flu (pulmonary flu) this year in Boston hospitalized hundreds and there were over 5 deaths. Mayor Minneno declared Boston an epidemic city. And immune system vaccination protocols are pretty straight forward to perform in clinics. I am looking forward to INSM saying they are filing a masterfile on the liposome.